Filspari (sparsentan) PDUFA Date (Travere Therapeutics)
FDA PDUFA decision date for Filspari (sparsentan) is April 13, 2026. Developed by Travere Therapeutics. Indication: Focal segmental glomerulosclerosis (FSGS). Current status: Approved.
Indication
Focal segmental glomerulosclerosis (FSGS)
Notes
Extended from Jan 13, 2026. Confirmatory endpoint data for accelerated approval conversion.
Regulatory details
- Company: Travere Therapeutics
- Therapeutic area: Rare Disease / Nephrology
- Application type: sNDA
- Review type: Standard
- PDUFA date: 2026-04-13
- Outcome: Approved